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Intercellular communication is a vital process in the function of all multicellular organisms.
Communication between liver cells is known to occur through multiple pathways including secreted mediators, direct cell-cell contact and by membrane surrounded particles referred (variably) to as extracellular vesicles (EVs) or exosomes. While the term exosome was initially reserved to describe vesicles that were released after the fusion of the multivesicular endosomes with the plasma membrane, it is likely that circulating EVs represent a heterogenous population of exosomes, microparticles or microvesicles in a size range of 40-100nm yet which are difficult to resolve using current purification methods (1). Exosomes are originally formed in the multivesicular endosomes whereas microvesicles are released by direct budding of the cell membrane (2) . EVs have been shown to be shed from most cells types, under both physiological conditions and in disease states. This process of shedding EVs from injured cells may have a pathogenic role in communicating danger or stress signals. EVs can interact with recipient cells by fusion, ligand-receptor interaction, or internalization via receptor-mediated endocytosis or micropinocytosis thus promoting uptake of their cargo (2) . From the perspective of fatty liver disease, it is important to note that serum biomarkers to detect progressive nonalcoholic steatohepatitis (NASH) are still lacking and so clinical and basic studies that advance our understanding of EVs in NASH patients and which may lead to diagnostic EV signatures that reflect histological progression are of substantial interest (3, 4) . are these findings so timely and important? First, macrophage recruitment is a key feature of progressive NASH, leading to a cascade of proinflammatory events and accelerating the progression of hepatic fibrosis (6) . Secondly, egress of bone marrow derived macrophages and recruitment to the liver is known to involve complex chemokine signaling, but local, lipidderived mediators of chemotaxis have not been previously described in the context of NASH.
These mediators and the signaling cascades elicited by specific lipid metabolites could be central to macrophage migration/activation, and targeting these events could be a potential therapeutic approach in NASH. Kakazu et al show that the ceramide metabolite sphingosine-1-phosphate (S1P) contained within lipotoxic EVs triggered S1PR1 signaling in macrophages, and furthermore demonstrated that inhibiting S1PR1 expression could mitigate macrophage migration. Further studies will be required to study the precise mechanisms of S1P recognition in macrophages and to resolve the question of whether other receptors could be involved.
Interestingly, a recent study demonstrated that hepatocyte exosomes that transfer sphingosine kinase 2 (SK2) to target hepatocytes can cause an increase in S1P and cell proliferation in models of ischemia/reperfusion or partial hepatectomy (7) . Therefore it is important to further precise mechanisms involved are yet to be discovered. Sphingolipid-containing raft membrane microdomains were previously shown to be required for cargo segregation in an alternative pathway of sorting, independent of the endosomal sorting complex required for transport (ESCRT) (9) , and these vesicle were enriched in ceramides. Thus it is possible that EVs generated from lipotoxic hepatocytes are actually derived from these membrane constituents.
To confirm the in vitro findings, the authors showed that EV C16 ceramide and EV S1P were significantly increased in patients with NASH compared to obese patients or those with simple hepatic steatosis. These data may indicate that EVs containing C16 ceramide or S1P play a role in the pathogenesis of NASH progression and/or could reflect disease stage.
Developing serum markers to detect disease progression in NASH is of major importance.
Circulating EVs have gained much attention in recent years as potential biomarkers in NASH (10, 11). Extensive characterization of serum EVs in animals with NASH led to the discovery of specific microRNA signatures with miR-122 and 192 (10) that was later confirmed in studies with NASH patients (11, 12) . In the current study, for the first time, EVs enriched in C16 ceramide/S1P were found in patients with early NASH. If confirmed in future clinical studies; these markers could become important tools for identifying patients at risk of necroinflammation and fibrosis. contribute to inflammation/fibrosis and whether they are indeed suitable and predictive serum biomarkers that might be used to detect progressive nonalcoholic fatty liver disease.
